Overview

Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Status:
Completed

Trial end date:
2014-05-01

Target enrollment:

Participant gender:

Summary

This phase II trial is studying how well a frailty index and geriatric assessment works in predicting toxicity to front-line chemotherapy in treating patients with stage IV non-small cell lung cancer. A frailty index and geriatric assessment prior to treatment may help identify a better treatment regimen

Details

Lead Sponsor:

Comprehensive Cancer Center of Wake Forest University
Wake Forest University Health Sciences

Collaborator:

National Cancer Institute (NCI)

Treatments:

Carboplatin